Summary of Zealand Pharma Conference Call Company Overview - **Company**: Zealand Pharma (OTCPK:ZLDP.Y) - **Date**: September 25, 2025 - **Key Speaker**: David M. Kendall, Chief Medical Officer Core Industry Insights Partnership and Product Development - Zealand Pharma has established a partnership with Roche, focusing on the petrelintide asset, which is progressing towards phase 3 trials [3][5] - Ongoing phase 2 studies are expected to yield results in the first half of next year [3] - The company aims to position itself as a key player in the obesity and metabolism space, beyond its existing Zegalogue franchise [4] Market Dynamics - The obesity market is evolving rapidly, with projections indicating that 40% to 50% of the global population will be overweight or obese in the coming decade [8] - There is a shift towards patient-driven demand for weight management therapies, contrasting with traditional provider-driven approaches [9][10] - Zealand Pharma believes that amylin-based therapies, particularly petrelintide, could become foundational in managing obesity [4][5] Product-Specific Insights Petrelintide Development - Petrelintide is expected to achieve weight loss comparable to GLP-1 therapies, with estimates of mid-teens to 20% weight loss [12][13] - The phase 2b trial aims to leverage tolerability and lower starting doses with monthly dose escalations [19] - The trial design will focus on a representative population, including a balanced gender ratio and higher BMI [20] Competitive Landscape - Petrelintide is positioned as a better-in-class option compared to other amylin agonists, with a 100% response rate in early studies [26] - The adverse event profile of petrelintide is expected to be favorable compared to competitors like kagrelintide and LRL-NTIDE [28][30] - Zealand Pharma is confident in the safety and efficacy of petrelintide, with no significant neuropsychiatric side effects reported [36][37] Regulatory and Market Considerations - The regulatory landscape is evolving, with expectations for higher efficacy and tolerability standards for new therapies [44][45] - Zealand Pharma is monitoring the potential for oral formulations but believes that injectables will remain the dominant delivery method in the obesity market [48][50] Future Outlook - Zealand Pharma is optimistic about the potential of petrelintide and its partnership with Roche to capture a significant share of the obesity market [11][35] - The company is preparing for phase 3 trials and is focused on optimizing trial designs to meet regulatory requirements and market needs [12][14] Conclusion - Zealand Pharma is strategically positioned in the growing obesity market with innovative therapies like petrelintide, backed by a strong partnership with Roche and a focus on patient-driven demand for weight management solutions [5][11]